Scarica l'app Stockscreener
32.54
4.15%
-1.41
Precedente Chiudi:
$33.95
Aprire:
$33.26
Volume 24 ore:
1.76M
Relative Volume:
0.76
Capitalizzazione di mercato:
$4.20B
Reddito:
-
Utile/perdita netta:
$-507.65M
Rapporto P/E:
-7.0739
EPS:
-4.6
Flusso di cassa netto:
$-616.24M
1 W Prestazione:
+2.17%
1M Prestazione:
-1.87%
6M Prestazione:
-63.25%
1 anno Prestazione:
-53.02%
Intervallo 1D:
$32.36
$33.80
Intervallo di 1 settimana:
$31.23
$36.84
Portata 52W:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Nome
Vaxcyte Inc
Settore
Industria
Telefono
650-837-0111
Indirizzo
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Confronta PCVX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
32.54 | 4.11B | 0 | -507.65M | -616.24M | -4.60 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Iniziato | Goldman | Buy |
| 2023-12-07 | Iniziato | Mizuho | Buy |
| 2023-04-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-03 | Reiterato | Needham | Buy |
| 2022-12-15 | Iniziato | Guggenheim | Buy |
| 2022-11-17 | Iniziato | BTIG Research | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-24 | Ripresa | Jefferies | Buy |
| 2020-07-07 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Iniziato | Needham | Buy |
Mostra tutto
Vaxcyte Inc Borsa (PCVX) Ultime notizie
How the (PCVX) price action is used to our Advantage - news.stocktradersdaily.com
James T. Wassil ’99G ’05G of Vaxcyte Inc., Tells Graduates ‘The Journey Ahead is Yours to Shape’ - Lehigh University
Transcript : Vaxcyte, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back? - MSN
Vaxcyte, Inc. Reports Q1 2025 Financial Results - TipRanks
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight - GuruFocus
Vaxcyte (PCVX) Advances Pneumococcal Vaccine Development | PCVX Stock News - GuruFocus
Vaxcyte Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Vaxcyte Inc Reports Q1 2025 EPS of -$1.04, Beating Estimates; Net Loss Widens to $140.7 Million - GuruFocus
Oversold Conditions For Vaxcyte (PCVX) - Nasdaq
Vaxcyte (PCVX) Stock Price, News & Analysis - MarketBeat
Vaxcyte appoints new independent director - Investing.com Australia
Vaxcyte appoints new independent director By Investing.com - Investing.com South Africa
Vaxcyte (PCVX) Welcomes Former Sanofi CEO to Board of Directors | PCVX Stock News - GuruFocus
Vaxcyte (PCVX) Welcomes Former Sanofi CEO to Board of Directors - GuruFocus
Vaxcyte Appoints Dr. Olivier Brandicourt to Board - TipRanks
Vaxcyte adds former Sanofi CEO to its board - Investing.com
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors | PCVX Stock News - GuruFocus
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - The Manila Times
Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now? - Yahoo Finance
US Stocks Dip As Investors Eye Trump's Tariff Announcements - Finimize
PCVXVaxcyte, Inc. Latest Stock News & Market Updates - Stock Titan
James T. Wassil ’99G ’05G of Vaxcyte, Inc. Named Lehigh’s 2025 Graduate Commencement and Doctoral Hooding Ceremony Speaker - Lehigh University
Vaxcyte (PCVX) Gains Attention with Overweight Rating Amid Marke - GuruFocus
Vaxcyte (PCVX) Sees Surge in Investor Interest Amid Biotech Buzz - GuruFocus
Vaxcyte (PCVX) Sees Surge in Investor Interest Amid Biotech Buzz | PCVX Stock News - GuruFocus
Commit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using Options - Nasdaq
TD Cowen Keeps Their Buy Rating on Vaxcyte (PCVX) - The Globe and Mail
When the Price of (PCVX) Talks, People Listen - news.stocktradersdaily.com
2 ‘Strong Buy’ Growth Stocks That Could Gain More Than 340% - The Globe and Mail
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason - MSN
Vaxcyte Stock Plummets: What’s Next? - timothysykes.com
Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential - Insider Monkey
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges - Investing.com India
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges By Investing.com - Investing.com South Africa
Vaxcyte (NASDAQ:PCVX) Price Target Lowered to $137.00 at Bank of America - MarketBeat
InvestingPro Fair Value model correctly predicted Vaxcyte’s decline By Investing.com - Investing.com UK
Vaxcyte (NASDAQ:PCVX) Given New $137.00 Price Target at Bank of America - Defense World
Vaxcyte Inc Azioni (PCVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
17.27%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):